Lauri M Burroughs, MD

Lauri M Burroughs, MD

Cancer and Blood Disorders Center, Non-Malignant Transplant Program, Pediatric Blood and Marrow Transplant Program

On staff since November 2004

Children's Title: Attending Physician, Blood and Marrow Transplantation Service

Academic Title: Associate Professor, Department of Pediatrics, University of Washington School of Medicine

Research Center: Ben Towne Center for Childhood Cancer Research

"The patients and families are really what motivate me to keep striving to do better. I am always amazed at the inner strength these kids and their parents have. It is so rewarding to be a part of their lives and help them through a really difficult time. To see a child pull through and come out the other side and thrive is a wonderful feeling."

  • Lauri M. Burroughs, MD, is attending physician at Seattle Children’s Hospital, associate professor in the Division of Pediatric Hematology/Oncology at the University of Washington School of Medicine and associate professor in the Clinical Research Division and in the Pediatric Stem Cell Transplantation Center at Fred Hutchinson Cancer Center. Her research interests include hematopoietic cell transplant for patients with primary immunodeficiencies and other nonmalignant inherited disorders, and she has focused her research efforts on reducing transplant-related complications.

    She is conducting several clinical trials evaluating reduced intensity or nonmyelobaltive conditioning followed by transplant for patients with nonmalignant disorders. One of the clinical trial is evaluating whether the addition of the T cell depleting agent Campath can decrease the incidence of graft versus host disease (GVHD) and improve donor chimerism following hematopoietic cell transplantation. In addition, in order to increase the number of patients with primary immunodeficiencies and other rare nonmalignant inherited diseases who may benefit from a transplant, Dr. Burroughs developed a clinical trial for patients who do not have an HLA-matched related or unrelated donor. Patients receiving a nonmyeloablative conditioning regimen will receive cyclophosphamide before and after hematopoietic cell transplantation followed by HLA-haploidentical grafts to remove alloreactive T cells with the goal of improving engraftment and decreasing GVHD. Finally, Dr. Burroughs is exploring a reduced intensity regimen that incorporates Treosulfan a Busulfan analog into the preparative regimen which in several clinical trials has been shown to be associated with significantly reduced toxicity and as a result decreased transplant related mortality following transplant. In collaboration with the Immunology group at Seattle Children's, Dr. Burroughs is evaluating how the immune system reconstitutes following transplant. 

    Be the first to recommend Lauri M Burroughs, MD

  • Other Publications

    • Burroughs LM, Torgerson TR, Storb R, Carpenter PA, Rawlings DJ, Sanders J, Scharenberg AM, Skoda-Smith S, Englund J, Ochs HD, Woolfrey AE
      Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome.
      20643476 The Journal of allergy and clinical immunology, 2010 Jul 17
    • Liu P, Santisteban I, Burroughs LM, Ochs HD, Torgerson TR, Hershfield MS, Rawlings DJ, Scharenberg AM
      Immunologic reconstitution during PEG-ADA therapy in an unusual mosaic ADA deficient patient.
      18952502 Clinical immunology (Orlando, Fla.), 2009 Feb. : 162-74

    Show More Hide

Overview

Board Certification(s)

Pediatrics
Pediatric Hematology-Oncology

Medical/Professional School

University of Wisconsin School of Medicine & Public Health, Madison, WI

Residency

Indiana University School of Medicine, Indianapolis, IN

Fellowship

University of Washington School of Medicine, Seattle, WA

Clinical Interests

Bone marrow transplantation for patients with nonmalignant and malignant diseases.

Research Description

Primary research focus is bone marrow transplantation for patients with nonmalignant diseases including primary immunodeficiency disorders, bone marrow failure syndromes, metabolic diseases, and hemoglobinopathies (sickle cell and thalassemia).